Psychiatry and Clinical Neurosciences
February 26, 2026
Kengo Yonezawa, Mika Hirata, Hiroaki Takano et al.
1 citation
Psilocybin, a classic psychedelic compound, has garnered renewed interest as a potential treatment for various psychiatric disorders. This review provides a comprehensive overview of psilocybin's history, recent clinical evidence, ongoing clinical trials, neuroimaging findings, and regulations. Historically used in spiritual and healing rituals, psilocybin was in the early 1970s subjected to...
AJN, American Journal of Nursing
February 19, 2026
Liz Braun, Alison Colbert
Ketamine has emerged as a promising intervention for treatment-resistant mental health disorders, such as depression, anxiety, and posttraumatic stress disorder. With rising global mental health burdens and the limitations of existing pharmacological treatments, ketamine's novel mechanism of action provides a potential alternative for individuals who have not responded to traditional therapies....
medRxiv
February 19, 2026
Amanda Gow, Emily Shih, Ryan Reid et al.
preprint
Abstract Background In 2020, Oregon became the first U.S. state to establish a regulated framework for adults to access psilocybin services using naturally-derived mushroom products. No studies have examined mental health outcomes among individuals receiving psilocybin in this context. Aims To evaluate changes in self-reported symptoms of depression, anxiety, and well-being 30-days...
Research Square
February 11, 2026
Jack Swain, Davis Carter, Leonardo Vando
preprint
Abstract Background: Post-traumatic stress disorder (PTSD) is a common mental health condition affecting approximately 3-6% of the U.S. adult population annually, and is characterized by intrusive symptoms, avoidance, negative cognitive and mood alterations, and hyperarousal following trauma exposure. Ketamine shows promise as a treatment for PTSD in preliminary trials, though real-world...
Geriatrics
February 5, 2026
Sanjay Shete, Anita Verma, Ranjeet Singh Bhogal et al.
Background: Advancing age is frequently associated with balance impairment, increased fall risk, and psychological distress, which together contribute to loss of independence and reduced quality of life. Yoga, as a mind-body practice, has the potential to enhance physical stability as well as mental well-being in older adults. Therefore, the objective of this study was to evaluate the effects...
Psychiatry Research
February 2, 2026
Tatiana Aboulafia Brakha, Albert Buchard, Cédric Mabilais et al.
1 citation
Classic serotonergic psychedelics such as LSD and psilocybin show promising antidepressant effects in controlled trials, but real-world data from routine clinical care remain limited. This study retrospectively analysed routine data from adults with treatment-resistant depressive and/or anxiety disorders who received a first standardized Psychedelic-assisted Psychotherapy (PAP) cycle with 100...
Brain and Behavior
February 1, 2026
Asim Shah, F N U Sawaira, Muneeb Shad Mohmand et al.
Background: Acute suicidality is an emergency psychiatric condition that requires urgent treatment. Traditional treatment approaches, such as antidepressant pharmacotherapy and psychotherapy, take weeks to achieve optimal effectiveness, hence exposing patients in imminent crisis to significant risk. Ketamine is a fast-acting N-methyl-D-aspartate (NMDA) receptor antagonist that has been...
Expert Opinion on Pharmacotherapy
February 1, 2026
Alessandro Cuomo, Mario Pinzi, Andrea Fagiolini
Major depressive disorder (MDD) remains a leading global cause of disability, with substantial clinical and societal burden. Despite the wide availability of antidepressants, many patients experience inadequate response, partial remission, or treatment-resistant depression. Emerging pharmacological options beyond traditional monoaminergic agents have shown promise in phase 3 clinical trials,...
Journal of the Royal Society of New Zealand
February 1, 2026
Neil McNaughton, Shabah M. Shadli, Ben Beaglehole et al.
The neurotic disorders (e.g., depression, dysthymia, generalized anxiety disorder, panic disorder, agoraphobia, social anxiety, post-traumatic stress disorder, and obsessive-compulsive disorder) are costly and difficult to treat. Diagnosis is based on symptoms not biological causes. Here, we summarize New Zealand-based work developing EEG biomarkers and novel treatments. Working at the...
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
February 1, 2026
Katarzyna Kała, Dorota Bederska‐łojewska, Jan Lazur et al.
The growing percentage of people suffering from drug-resistant depression increases interest in alternative therapies, particularly the usage of psychedelics such as psilocybin. The main source of psilocybin is the Psilocybe cubensis species. Due to the potential therapeutic benefits of psilocybin and the legal restrictions on its possession and use in the form of fungal fruiting bodies, this...